Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM31VNC)

• Drug Name: DS-8895 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 21894761
  TTD Drug ID: DM31VNC

Molecule-Related Drug Atlas

Drug(s) Targeting Ephrin type-A receptor 2 (EPHA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CAR-T cells targeting EphA2	DMN3C2I	Malignant glioma	2A00.0	Phase 1/2	[4]
BT5528	DMYBKMV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[5]
MEDI-547	DM3WP70	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
MEDI-543	DM7Q1PF	Solid tumour/cancer	2A00-2F9Z	Preclinical	[7]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[8]
PMID23489211C20	DMDYC4J	Discovery agent	N.A.	Investigative	[9]
PMID19788238C66	DMCVJK9	Discovery agent	N.A.	Investigative	[10]
PMID21561767C8h	DMABZH6	Discovery agent	N.A.	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ephrin type-A receptor 2 (EPHA2)	TTRJB2G	EPHA2_HUMAN	Not Available	[2] , [3]

References

• [1] ClinicalTrials.gov (NCT02252211) Safety and Bio-Imaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Daiichi Sankyo.
• [3] Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
• [4] ClinicalTrials.gov (NCT02575261) CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
• [5] MMAE Delivery Using the Bicycle Toxin Conjugate BT5528. Mol Cancer Ther. 2020 Jul;19(7):1385-1394.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1822).
• [7] Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15;10(12):1306-14.
• [8] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [9] Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
• [10] Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
• [11] Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.